Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jgg.2017.06.001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Terminal α1,2-fucosylation of glycosphingolipids by FUT1 is a key regulator in early cell-fate decisions.
EMBO Rep
October 2024
Avram and Stella Goren-Goldstein Department of Biotechnology Engineering, Faculty of Engineering Sciences, Ben-Gurion University of the Negev, Beer-Sheva, 8410501, Israel.
Article Synopsis
- The study investigates how glycosphingolipids (GSLs), specifically α1,2-fucosylated GSLs, influence the differentiation of human pluripotent cells (hPCs) during early embryogenesis.
- Overexpression of these GSLs hinders hPC differentiation into mesodermal cells and cardiomyocytes, while their reduction enhances differentiation and responsiveness to external signals such as BMP4.
- The research suggests that α1,2-fucosylated GSLs play a crucial role in regulating cell signaling pathways involved in early embryo development and cell fate decisions.
Integrative analysis of the ethanolamine utilization bacterial microcompartment in .
mSystems
August 2024
Toulouse Biotechnology Institute, Université de Toulouse, CNRS, INRAE, INSA, Toulouse, France.
Bacterial microcompartments (BMCs) are self-assembling protein megacomplexes that encapsulate metabolic pathways. Although approximately 20% of sequenced bacterial genomes contain operons encoding putative BMCs, few have been thoroughly characterized, nor any in the most studied strains. We used an interdisciplinary approach to gain deep molecular and functional insights into the ethanolamine utilization (Eut) BMC system encoded by the operon in K-12.
View Article and Find Full Text PDFDesigning functionalized nanodiamonds with hyaluronic acid-phospholipid conjugates for enhanced cancer cell targeting and fluorescence imaging capabilities.
Nanoscale
June 2024
Department of Physics, University of Torino, via P. Giuria 1, 10125 Torino, Italy.
Nanomedicine aims to develop smart approaches for treating cancer and other diseases to improve patient survival and quality of life. Novel nanoparticles as nanodiamonds (NDs) represent promising candidates to overcome current limitations. In this study, NDs were functionalized with a 200 kDa hyaluronic acid-phospholipid conjugate (HA/DMPE), enhancing the stability of the nanoparticles in water-based solutions and selectivity for cancer cells overexpressing specific HA cluster determinant 44 (CD44) receptors.
View Article and Find Full Text PDFTargeting pentamidine towards CD44-overexpressing cells using hyaluronated lipid-polymer hybrid nanoparticles.
Drug Deliv Transl Res
August 2024
Dipartimento di Scienza e Tecnologia del Farmaco, Università di Torino, Torino, Italy.
Biodegradable nanocarriers possess enormous potential for use as drug delivery systems that can accomplish controlled and targeted drug release, and a wide range of nanosystems have been reported for the treatment and/or diagnosis of various diseases and disorders. Of the various nanocarriers currently available, liposomes and polymer nanoparticles have been extensively studied and some formulations have already reached the market. However, a combination of properties to create a single hybrid system can give these carriers significant advantages, such as improvement in encapsulation efficacy, higher stability, and active targeting towards specific cells or tissues, over lipid or polymer-based platforms.
View Article and Find Full Text PDFIRAK4 degrader in hidradenitis suppurativa and atopic dermatitis: a phase 1 trial.
Nat Med
December 2023
Kymera Therapeutics, Inc., Watertown, MA, USA.
Toll-like receptor-driven and interleukin-1 (IL-1) receptor-driven inflammation mediated by IL-1 receptor-associated kinase 4 (IRAK4) is involved in the pathophysiology of hidradenitis suppurativa (HS) and atopic dermatitis (AD). KT-474 (SAR444656), an IRAK4 degrader, was studied in a randomized, double-blind, placebo-controlled phase 1 trial where the primary objective was safety and tolerability. Secondary objectives included pharmacokinetics, pharmacodynamics and clinical activity in patients with moderate to severe HS and in patients with moderate to severe AD.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!